Francesco Crea

Prof. Dr. Francesco Crea

Senior Lecturer and Research Director, Department of Life, Health and Chemical Sciences, Open University, Milton Keynes, United Kingdom

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2014 in Oncotarget
Verified
Journal Article
Open access
PDF file
FCFrancesco Crea
Francesco Crea
AWAkira Watahiki
Akira Watahiki
LQLuca Quagliata
Luca Quagliata
HXHui Xue
Hui Xue
LPLarissa Pikor
Larissa Pikor
CHCheryl Helgason
Cheryl Helgason
Metastatic prostate cancer (PCa) is still an incurable disease. Long non-coding RNAs (lncRNAs) may be an overlooked source of cancer biomarkers and therapeutic targets. We therefore performed RNA sequencing on paired metastatic/non-metastatic PCa xenografts derived from clinical specimens. The most highly up-regulated transcript was LOC728606, a lncRNA now designated PCAT18. PCAT18 is specifically expressed in the prostate compared to 11 other normal tissues (p<0.05) and up-regulated in PCa compared to 15 other neoplasms (p<0.001). Cancer-specific up-regulation of PCAT18 was confirmed on an independent dataset of PCa and benign prostatic hyperplasia samples (p<0.001). PCAT18 was detectable in plasma samples and increased incrementally from healthy individuals to those with localized and metastatic PCa (p<0.01). We identified a PCAT18-associated expression signature (PES), which is highly PCa-specific and activated in metastatic vs. primary PCa samples (p<1E-4, odds ratio>2). The PES was significantly associated with androgen receptor (AR) signalling. Accordingly, AR activation dramatically up-regulated PCAT18 expression in vitro and in vivo. PCAT18 silencing significantly (p<0.001) inhibited PCa cell proliferation and triggered caspase 3/7 activation, with no effect on non-neoplastic cells. PCAT18 silencing also inhibited PCa cell migration (p<0.01) and invasion (p<0.01). These results position PCAT18 as a potential therapeutic target and biomarker for metastatic PCa.

1 June 2021 in Cancer Letters
Verified
Journal Article
Closed access
SASaeed Ashrafizaveh
Saeed Ashrafizaveh
MAMilad Ashrafizadeh
Milad Ashrafizadeh
Ali ZarrabiAli Zarrabi
Ali Zarrabi
KHKiavash Husmandi
Kiavash Husmandi
AZAmirhossein Zabolian
Amirhossein Zabolian
KAKwang Seok Ahn
Kwang Seok Ahn

18 April 2011 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
FCFrancesco Crea
Francesco Crea
EHElaine M Hurt
Elaine M Hurt
LMLesley A Mathews
Lesley A Mathews
SCStephanie M Cabarcas
Stephanie M Cabarcas
LSLei Sun
Lei Sun
WFWilliam L Farrar
William L Farrar
Background: Polycomb repressive complex 2 (PRC2) mediates gene silencing through histone H3K27 methylation. PRC2 components are over-expressed in metastatic prostate cancer (PC), and are required for cancer stem cell (CSC) self-renewal. 3-Dezaneplanocin-A (DZNeP) is an inhibitor of PRC2 with broad anticancer activity. Method: we investigated the effects of DZNeP on cell proliferation, tumorigenicity and invasive potential of PC cell lines (LNCaP and DU145). Results: Exploring GEO and Oncomine databases, we found that specific PRC2 genes (EED, EZH2, SUZ12) predict poor prognosis in PC. Non-toxic DZNeP concentrations completely eradicated LNCaP and DU145 prostatosphere formation, and significantly reduced the expression of CSC markers. At comparable doses, other epigenetic drugs were not able to eradicate CSCs. DZNeP was also able to reduce PC cell invasion. Cells pre-treated with DZNeP were significantly less tumorigenic (LNCaP) and formed smaller tumors (DU145) in immunocompromised mice. Conclusion: DZNeP is effective both in vitro and in vivo against PC cells. DZNeP antitumor activity is in part mediated by inhibition of CSC tumorigenic potential.

19 June 2012 in Cancer and Metastasis Reviews
Verified
Journal Article
Closed access
PDF file
FCFrancesco Crea
Francesco Crea
LFLorenzo Fornaro
Lorenzo Fornaro
GBGuido Bocci
Guido Bocci
LSLei Sun
Lei Sun
WFWilliam L. Farrar
William L. Farrar
RDRomano Danesi
Romano Danesi

1 December 2011 in Drug Resistance Updates
Verified
Journal Article
Closed access
FCFrancesco Crea
Francesco Crea
Stefania NobiliStefania Nobili
Stefania Nobili
EPElisa Paolicchi
Elisa Paolicchi
GPGabriele Perrone
Gabriele Perrone
CNCristina Napoli
Cristina Napoli
Enrico MiniEnrico Mini
Enrico Mini

Verified
Journal Article
Open access
PDF file
AWAkira Watahiki
Akira Watahiki
RMRobyn J. Macfarlane
Robyn J. Macfarlane
MGMartin E. Gleave
Martin E. Gleave
FCFrancesco Crea
Francesco Crea
Yuzhuo WangYuzhuo Wang
Yuzhuo Wang
KCKim N Chi
Kim N Chi
MicroRNAs (miRNAs) have emerged as key regulators of numerous biological processes, and increasing evidence suggests that circulating miRNAs may be useful biomarkers of clinical disease. In this study, we sought to identify plasma miRNAs that differentiate patients with metastatic castration resistant prostate cancer (mCRPC) from those with localized prostate cancer (PCa). Pooled plasma samples from patients with localized PCa or mCRPC (25 per group) were assayed using the Exiqon miRNA qPCR panel, and the differential expression of selected candidates was validated using qRT-PCR. We identified 63 miRNAs upregulated in mCRPC versus localized PCa, while only four were downregulated. Pearson’s correlation analysis revealed two highly correlated groups: one consisting of miR-141, miR375 and miR-200c and the other including miR151-3p, miR423-3p, miR-126, miR152 and miR-21. A third group, containing miR-16 and miR-205, showed less correlation. One miRNA from each group (miR-141, miR151-3p and miR-16) was used for logistic regression analysis and proved to increase the sensitivity of the prostate-specific antigen (PSA) test alone. While no miRNA alone differentiated localized PCa and mCRPC, combinations had greater sensitivity and specificity. The expression of these 10 candidates was assayed for association with clinical parameters of disease progression through the cBio portal. Our results demonstrate that plasma levels of selected miRNAs are potential biomarkers to differentiate localized PCa and mCRPC.